$ICUI

FINNEY ELISHA W sold $69K of ICUI

FINNEY ELISHA W sold 378 shares of ICU MEDICAL INC/DE (ICUI) at $182.48 on 2026-08-11.

Original reporting
SEC EDGAR · FINNEY ELISHA W
Published Aug 11, 2026, 9:59 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 10:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ICUI
Neutral
low confidence
Mentioned
$ICUI
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ICUINeutralLow
01

Why it matters

Insider selling can be interpreted as caution, but without additional disclosures (earnings, guidance, litigation, or operational changes) it is usually not a strong standalone trading catalyst.

02

Market read

Traders may briefly reassess sentiment around ICUI due to the director sale, but the filing alone is unlikely to drive a durable repricing.

03

What to watch

The transaction size is modest relative to typical institutional flows, and the article lacks context on total holdings, prior sales cadence, or reasons for the sale.

Relevance 3/10Novelty 3/10Timing: filed on 2026-08-11 (after-hours)

Background

The article is an SEC Form 4 insider transaction disclosure for ICU Medical, Inc. (ICUI).

Company-level read

Ticker impact

$ICUINeutralLow confidence
Context

ICU Medical director Elisha W Finney filed a Form 4 selling 378 shares at $182.4818 on 2026-08-11, totaling about $68,978.

Expected impact

Low likelihood of sustained price impact; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a small, non-10b5-1 sale by a director, but the article provides no accompanying fundamental change, guidance, or enforcement context.

Market effects

Minimal; this is company-specific insider activity with no sector-wide catalyst described.

None indicated.

None indicated.

Counterpoint

The sale may be planned for liquidity or diversification, and the absence of a 10b5-1 plan does not necessarily imply negative fundamentals.

Key entities

  • ICU Medical, Inc.

    Company whose director insider sale is disclosed via SEC Form 4.

  • Elisha W. Finney

    Director who sold 378 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ICUIMed

ICU Medical rating upgraded by S&P on stronger credit metrics

S&P Global Ratings upgraded ICU Medical Inc. to 'BB' from 'BB-', citing improved credit metrics and strong operating performance. The company's adjusted leverage decreased to 3.1x in Q2 2026, with free operating cash flow exceeding expectations. ICU Medical used proceeds from asset sales and cash flow to reduce debt. S&P projects mid-single-digit revenue growth and margin improvement through 2027, with a stable outlook based on expected debt and cash flow metrics.

$ICUIMedAI 8/10

ICU Medical (ICUI) Q2 2026 Earnings Call Transcript

ICU Medical (ICUI) reported Q2 2026 revenue of $551.7M, up 1% reported and 6% organic excluding IV Solutions divestiture and currency. Infusion Systems revenue was $189.0M (+12% organic), Consumables $289.3M (+5% organic). Adjusted EBITDA was $110.0M (+10%). Full-year guidance raised to $415M-$435M EBITDA and $8.60-$9.00 EPS.

$ICUIHighAI 9/10

ICU Medical (ICUI) Shares Skyrocket, What You Need To Know

ICU Medical (NASDAQ:ICUI) shares rose 10.2% after the company reported Q2 results that beat Wall Street and lifted full-year guidance. Adjusted EPS was $2.37 vs $1.91 expected, revenue was $551.7 million vs forecasts, and free cash flow improved to $61.64 million. Full-year adjusted EPS guidance was raised to $8.80 (midpoint).

$ICUIHighAI 9/10

ICU Medical (ICUI) Shares Skyrocket, What You Need To Know

ICU Medical (NASDAQ: ICUI) shares rose 10.2% after the company reported Q2 adjusted EPS of $2.37, above the $1.91 consensus, and revenue of $551.7 million, above forecasts. Free cash flow improved to $61.64 million from -$8.49 million a year earlier. ICU Medical raised full-year adjusted earnings guidance to $8.80 per share (midpoint).

$ICUIMedAI 8/10

ICU Medical (NASDAQ:ICUI) Reports Strong Q2 CY2026

ICU Medical (NASDAQ:ICUI) reported Q2 CY2026 results. Revenue rose 1.5% year over year to $551.7 million, beating Wall Street’s revenue estimate by 3.5%. Non-GAAP adjusted EPS was $2.37, up from $2.10 and 23.8% above consensus. The stock rose 1.4% to $168.02 after the release.